Key result
A 24-year-old woman with COVID-19 developed reverse takotsubo cardiomyopathy shortly after receiving Casirivimab-Imdevimab monoclonal antibody infusion therapy.
Case Report (n=1)
No
This case highlights the rare occurrence of reverse takotsubo cardiomyopathy in a young woman with COVID-19 following casirivimab-imdevimab therapy, emphasizing the need to consider cardiomyopathies as potential consequences in this population.
Reverse Takotsubo case in middle-aged woman extends phenotypic descriptions; hypothesis-generating and should not change practice.
BACKGROUND Takotsubo cardiomyopathy, also referred to as apical ballooning syndrome (ABS), stress cardiomyopathy, or broken heart syndrome, initially described in Japan, is characterized by transient wall motion abnormalities involving the apical segment. Several variants have been described, including reverse type, mid-ventricular type, and the focal type. In the reverse type, there is basal hypokinesis and apical hyperkinesis. Stress cardiomyopathy is most likely to occur in middle-aged women and the underlying etiology is believed to be related to catecholamine release due to intense stress. CASE REPORT We report an extremely rare case of reverse takotsubo cardiomyopathy (rTTC) in a young woman with COVID-19 who was treated with Casirivimab-Imdevimab therapy. Our report is the second to reveal rTTC in a patient with COVID-19 in which obstructive coronary artery disease was definitively ruled out by coronary CT angiography. CONCLUSIONS Cardiovascular involvement in COVID-19 has been linked to increased morbidity and mortality rates. Recent reports have suggested the occasional occurrence of TTC and the rare occurrence of reverse takotsubo cardiomyopathy (rTTC) in patients with COVID-19. In fact, to the best of our knowledge, this is only the fifth reported case of rTTC in a patient with COVID-19; importantly, 3 out of the 4 of the previous reported cases lacked definitive ischemic work-up to rule out obstructive coronary artery disease due to the critical condition of the patients.
No takes yet. Share an insight, caveat, or question.
Salehin et al. (2022) conducted a case report in COVID-19 and Reverse Takotsubo Cardiomyopathy (n=1). Casirivimab-Imdevimab was evaluated on Development of reverse takotsubo cardiomyopathy. A 24-year-old woman with COVID-19 developed reverse takotsubo cardiomyopathy shortly after receiving Casirivimab-Imdevimab monoclonal antibody infusion therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: